INI-1 Immunohistochemistry at Lahore PCR Lab

Understanding INI-1 Immunohistochemistry at Lahore PCR Lab

Immunohistochemistry (IHC) represents a cornerstone of modern diagnostic pathology, bridging the gap between cellular morphology and molecular genetics. Among the diverse array of immunohistochemical markers utilized in contemporary oncology, the Integrase Interactor 1 (INI-1) protein—also known as SMARCB1, BAF47, or SNF5—stands out as a critical diagnostic tool. The INI-1 Immunohistochemistry test at Lahore PCR Lab in Lahore, Pakistan, is a highly specialized laboratory investigation designed to evaluate the expression of the INI-1 tumor suppressor protein in tissue specimens. This diagnostic assay plays a pivotal role in the identification, classification, and differential diagnosis of several highly aggressive pediatric and adult neoplasms, particularly those affecting the central nervous system, kidneys, and soft tissues.

By utilizing monoclonal antibodies directed against the INI-1 protein, pathologists at Lahore PCR Lab can precisely determine whether the protein is present or absent within the nuclei of tumor cells. Under normal physiological conditions, the SMARCB1 gene, located on the long arm of chromosome 22 (22q11.2), actively encodes the INI-1 protein, which serves as a core subunit of the SWI/SNF (SWItch/Sucrose Non-Fermentable) ATP-dependent chromatin-remodeling complex. This complex is essential for regulating gene expression, maintaining genomic stability, and controlling cell cycle progression. When both alleles of the SMARCB1 gene undergo inactivation due to mutations, deletions, or epigenetic silencing, the synthesis of the INI-1 protein is completely halted. Consequently, immunohistochemical staining reveals a complete loss of nuclear INI-1 expression in the neoplastic cells, while surrounding non-neoplastic cells, such as endothelial cells, lymphocytes, and stromal fibroblasts, retain strong nuclear staining, serving as built-in internal positive controls.

The clinical utility of this test is profound; it allows oncologists and pathologists to differentiate highly aggressive atypical teratoid/rhabdoid tumors (ATRT) from other embryonal central nervous system tumors, confirm diagnoses of epithelioid sarcoma, and identify malignant rhabdoid tumors of the kidney and extrarenal soft tissues. At Lahore PCR Lab, this advanced diagnostic test is performed using state-of-the-art automated staining platforms and evaluated by highly experienced consultant pathologists, ensuring the highest standards of diagnostic accuracy, clinical reliability, and rapid turnaround times for patients across Lahore and Pakistan.

Clinical Procedure: What to Expect

Patient Preparation

• Tissue Specimen Submission: Since this test is performed on tissue already removed from the patient, no direct physical preparation (such as fasting) is required. Patients must submit the formalin-fixed paraffin-embedded (FFPE) tissue block.
• Pathology Slides: Provide the corresponding hematoxylin and eosin (H&E) stained pathology slides from the initial biopsy or surgical procedure.
• Original Histopathology Report: Submit a complete copy of the original histopathology report associated with the tissue specimen.
• Clinical History: Provide detailed clinical information, including the patient’s age, tumor location, radiological findings, and suspected clinical diagnosis.
• Specimen Transport: Ensure that the tissue block and slides are transported in a secure, temperature-controlled container to prevent damage or degradation during transit to Lahore PCR Lab.

During the Procedure

The laboratory phase of the INI-1 Immunohistochemistry test at Lahore PCR Lab involves a series of highly controlled, sequential steps executed by skilled histotechnologists and evaluated by consultant pathologists. Once the FFPE tissue block is received and registered, ultra-thin sections measuring approximately 3 to 4 micrometers are cut using a high-precision rotary microtome. These tissue sections are carefully mounted onto specialized, positively charged glass slides to prevent tissue detachment during subsequent processing. The slides are then subjected to deparaffinization using xylene and rehydrated through a series of descending grades of alcohol.

To expose the target INI-1 antigen, which may have been masked during formalin fixation, the slides undergo heat-induced epitope retrieval (HIER) using a buffer solution of controlled pH within an automated immunohistochemistry stainer. Following antigen retrieval, endogenous peroxidase activity is blocked to prevent non-specific background staining. The tissue sections are then incubated with a highly specific, primary monoclonal antibody directed against the INI-1 (SMARCB1) protein. After thorough washing, a secondary detection system, typically a horseradish peroxidase (HRP)-labeled polymer, is applied, which binds to the primary antibody. The addition of a chromogen substrate, such as 3,3′-diaminobenzidine (DAB), produces a visible, insoluble brown precipitate at the site of the antigen-antibody complex within the cell nuclei. The slides are counterstained with hematoxylin to visualize cellular morphology, dehydrated, cleared, and coverslipped. Finally, a consultant pathologist examines the stained slides under a high-resolution light microscope, carefully evaluating the tumor cells for the presence or absence of nuclear staining while verifying that internal control cells exhibit strong, diffuse nuclear positivity.

When is an INI-1 Immunohistochemistry Test Performed?

Diagnosis of Atypical Teratoid/Rhabdoid Tumors (ATRT)

Atypical Teratoid/Rhabdoid Tumor (ATRT) is an extremely aggressive, fast-growing malignant tumor of the central nervous system that primarily affects infants and young children under the age of three. Patients often present with symptoms of increased intracranial pressure, including persistent vomiting, morning headaches, lethargy, irritability, macrocephaly, and cranial nerve palsies. Because ATRT closely mimics other embryonal tumors of the brain, such as medulloblastoma, primitive neuroectodermal tumors, and ependymomas, on both radiological imaging and routine H&E staining, making a definitive diagnosis is exceptionally challenging. Physicians request the INI-1 Immunohistochemistry test at Lahore PCR Lab to resolve this diagnostic dilemma. A complete loss of nuclear INI-1 expression in the tumor cells is the diagnostic hallmark of ATRT, enabling pathologists to confidently distinguish it from medulloblastomas and ependymomas, which consistently retain normal INI-1 expression.

Evaluation of Epithelioid Sarcoma

Epithelioid sarcoma is a rare, highly malignant soft tissue sarcoma that typically arises in the deep soft tissues of the distal extremities, such as the hands, forearms, and feet, of young adults. It often presents as a firm, painless, slow-growing nodule that may eventually ulcerate, mimicking a chronic inflammatory process, non-healing ulcer, or benign infectious granuloma. Due to its epithelioid morphology, it can easily be misdiagnosed as squamous cell carcinoma, melanoma, or epithelioid angiosarcoma. Oncologists and surgeons request an INI-1 IHC test at Lahore PCR Lab when evaluating suspicious epithelioid soft tissue lesions. Approximately 90% of epithelioid sarcomas exhibit a complete loss of INI-1 expression due to SMARCB1 gene inactivation. Identifying this loss is instrumental in confirming the diagnosis of epithelioid sarcoma and ruling out other epithelioid neoplasms that retain INI-1, thereby guiding appropriate surgical resection and oncological management.

Identification of Malignant Rhabdoid Tumors (MRT)

Malignant Rhabdoid Tumor (MRT) is an exceedingly rare and highly aggressive neoplasm that typically develops in the kidneys (renal MRT) or extrarenal soft tissues of infants and young children. Clinical symptoms often include a rapidly enlarging abdominal mass, hematuria, abdominal pain, fever, and weight loss. These tumors are characterized by rapid metastasis and a poor prognosis, requiring immediate and aggressive therapeutic intervention. Because MRT can morphologically resemble other pediatric renal tumors, such as Wilms tumor, clear cell sarcoma of the kidney, and congenital mesoblastic nephroma, precise pathological identification is crucial. Pediatric oncologists rely on the INI-1 Immunohistochemistry test at Lahore PCR Lab to confirm the diagnosis. The absolute absence of nuclear INI-1 staining in the rhabdoid cells confirms the diagnosis of MRT, allowing the clinical team to initiate targeted, high-intensity chemotherapy and surgical planning without delay.

Differential Diagnosis of Pediatric Brain Tumors

The differential diagnosis of pediatric brain tumors is one of the most complex areas in neuropathology. When an infant or young child presents with a posterior fossa mass, the differential diagnosis typically includes medulloblastoma, atypical teratoid/rhabdoid tumor (ATRT), choroid plexus carcinoma, and ependymoma. While these tumors may share overlapping histological features on routine light microscopy, their clinical behavior, prognosis, and response to chemotherapy and radiation differ significantly. Neurologists and neuro-oncologists frequently order the INI-1 IHC test at Lahore PCR Lab as part of a comprehensive diagnostic antibody panel. Since medulloblastomas and ependymomas retain nuclear INI-1 expression, while ATRT shows a complete loss, this single marker provides definitive diagnostic clarity. Accurate classification ensures that young patients receive the most appropriate, tumor-specific therapeutic regimens, minimizing treatment-related toxicities while maximizing survival outcomes.

Workup for Schwannomatosis and Familial Cancer Syndromes

Schwannomatosis is a rare genetic disorder characterized by the development of multiple non-cancerous tumors of the nervous system, called schwannomas, throughout the body, excluding the vestibular nerves. Patients often suffer from chronic, severe, and debilitating pain, localized numbness, tingling, and muscle weakness. Schwannomatosis is genetically linked to germline mutations in the SMARCB1 (INI1) or LZTR1 genes. When a patient presents with multiple schwannomas, pathologists and geneticists utilize the INI-1 Immunohistochemistry test at Lahore PCR Lab to evaluate the tumor tissue. In schwannomatosis-associated schwannomas, IHC typically reveals a characteristic mosaic or partial loss of INI-1 expression, whereas sporadic schwannomas show diffuse, intact nuclear expression. This specialized finding serves as a strong clinical indicator of a germline predisposition, guiding subsequent genetic testing, family screening, and long-term clinical surveillance for associated familial cancer syndromes.

What Does an INI-1 Immunohistochemistry Test Detect?

The INI-1 Immunohistochemistry test is a highly sensitive and specific molecular assay that detects the presence or absence of the INI-1 (SMARCB1) protein within cell nuclei. The primary findings and clinical detections associated with this test include:

• Retained Nuclear Expression: Normal, healthy cells and most non-rhabdoid tumors show strong, diffuse nuclear staining, indicating a wild-type SMARCB1 gene.
• Complete Loss of Expression: Neoplastic cells show an absolute absence of nuclear staining, confirming biallelic inactivation of the SMARCB1 gene.
• Atypical Teratoid/Rhabdoid Tumor (ATRT) Confirmation: Confirms the diagnosis of ATRT in pediatric central nervous system embryonal tumors.
• Epithelioid Sarcoma Identification: Confirms the diagnosis of both classic and proximal-type epithelioid sarcomas.
• Malignant Rhabdoid Tumor (MRT) Diagnosis: Confirms renal and extrarenal malignant rhabdoid tumors in pediatric patients.
• Mosaic Loss of Expression: Detects partial or mosaic nuclear staining patterns characteristic of schwannomatosis-associated schwannomas.
• Exclusion of Medulloblastoma: Helps rule out medulloblastoma, which consistently retains nuclear INI-1 expression.
• Exclusion of Ependymoma: Helps rule out ependymoma, which shows intact nuclear INI-1 expression.
• Exclusion of Synovial Sarcoma: Differentiates epithelioid sarcoma from synovial sarcoma, which retains INI-1 expression.
• Exclusion of Epithelioid Angiosarcoma: Helps distinguish epithelioid sarcoma from vascular neoplasms that retain nuclear INI-1.
• Exclusion of Melanoma: Differentiates poorly differentiated epithelioid tumors from melanoma, which retains INI-1.
• Poorly Differentiated Chordoma Detection: Identifies loss of INI-1 expression in aggressive, poorly differentiated chordomas.
• Epithelioid MPNST Identification: Detects loss of INI-1 in epithelioid malignant peripheral nerve sheath tumors.
• Myoepithelial Carcinoma Detection: Identifies INI-1 deficiency in myoepithelial neoplasms of soft tissue and salivary glands.
• Internal Positive Control Validation: Verifies the presence of nuclear staining in non-neoplastic lymphocytes, confirming staining quality.
• Endothelial Cell Control Validation: Verifies nuclear staining in vascular endothelial cells as an internal technical control.
• Stromal Fibroblast Control Validation: Verifies nuclear staining in background stromal fibroblasts.
• Technical Staining Integrity: Detects potential technical failures if internal controls fail to stain.
• Preservation of Antigenic Sites: Confirms proper tissue fixation and processing.
• Absence of Background Artifacts: Confirms high-quality, clean antibody staining without non-specific background noise.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for pathology results can be an anxious time for patients and their families, especially when dealing with suspected malignancies. The INI-1 Immunohistochemistry test is a highly specialized, multi-step molecular pathology assay that requires meticulous technical execution and detailed microscopic analysis. Typically, the turnaround time for this test is 3 to 5 working days from the time the tissue block and clinical documentation are received at our state-of-the-art laboratory in Lahore. This timeframe ensures that our histotechnologists can perform precise antigen retrieval and staining, and our consultant pathologists can thoroughly review the slides, including all internal and external controls.

Once the diagnostic report is finalized and signed off by our expert pathologist, patients and referring physicians can access the report immediately through Lahore PCR Lab’s secure online portal. Additionally, automated SMS alerts are sent to the patient’s registered mobile number, providing a direct link to download the digital report. Physical copies of the report can also be collected from our main diagnostic center or designated collection points across Lahore.

INI-1 Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CNS Embryonal Tumors	Retained nuclear INI-1 expression	Complete loss of nuclear INI-1 expression (ATRT)
Soft Tissue Epithelioid Tumors	Retained nuclear INI-1 expression	Complete loss of nuclear INI-1 expression (Epithelioid Sarcoma)
Pediatric Renal Masses	Retained nuclear INI-1 expression	Complete loss of nuclear INI-1 expression (Malignant Rhabdoid Tumor)
Peripheral Nerve Sheath Tumors	Retained nuclear INI-1 expression	Mosaic or partial loss of nuclear INI-1 expression (Schwannomatosis)
Internal Control Cells (Lymphocytes)	Strong, diffuse nuclear staining	Absence of staining (indicates technical or staining failure)
Vascular Endothelial Cells	Strong, diffuse nuclear staining	Absence of staining (indicates technical or staining failure)
Stromal Fibroblasts	Strong, diffuse nuclear staining	Absence of staining (indicates technical or staining failure)
Chordoma Subtypes	Retained nuclear INI-1 expression	Loss of nuclear INI-1 expression (Poorly Differentiated Chordoma)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for INI-1 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in oncopathology and molecular diagnostics.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards, ensuring highly accurate and reproducible test results.
• Professional Reporting: Our diagnostic reports are comprehensive, detailed, and structured to provide clear, actionable insights for referring oncologists.
• Modern Diagnostic Approach: We utilize state-of-the-art automated immunohistochemistry platforms to minimize human error and optimize staining quality.
• Comfortable Environment: Our diagnostic facilities in Lahore are designed to provide a professional, clean, and welcoming environment for all visitors.
• Convenient Location: Easily accessible main laboratory and multiple collection centers located strategically across Lahore, Pakistan.
• Commitment to Accurate Diagnosis: We are dedicated to delivering precise molecular and histopathological diagnoses to guide effective clinical decision-making.